Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Common Stock · CUSIP: 35104E100
Event date: 2024-12-31
- Filing-level shares
- 2,252,240
- Percent of class
- 4.9%
- JANUS HENDERSON GROUP PLC
Shares: 2,252,240 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001274173-25-000045
- Form type
- SCHEDULE 13G/A
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership